Current UK regulatory position includes: Warnings and precautions regarding thyroid C-cell tumours based on animal data, with acknowledgement that human relevance is uncertain Advice regarding pancreatitis risk, with recommendations to discontinue if acute pancreatitis is suspected and not to restart if confirmed No restrictions based on general cancer risk, as human evidence does not support an increased overall malignancy risk Monitoring for gallbladder disease, which has been associated with GLP-1 receptor agonist use The Summary of Product Characteristics (SmPC) for each GLP-1 medicine includes detailed safety information that healthcare professionals should review before prescribing
Retrieved from Qian, L., Wang, W., Zhou, Y., & Ma, J
These mechanisms necessitate further investigation into the pathways of GLP-1RA involvement in the clinical course of DR to learn if they hold substantial value beyond a pre-clinical setting [91]
Gao Y, Peterson E, Pagidipati N
An investigation by the Houston Chronicle found that state and federal oversight efforts are murky with compounding pharmacies because they dont have to disclose reports of patient harm
Tesamorelin: The Approved GHRH Analog Structure and Development Tesamorelin is a synthetic peptide consisting of the 44-amino-acid sequence of human GHRH with an added trans-3-hexenoic acid group at the N-terminus for stability
